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Abstract:  CMX001,  a  lipophilic  nucleotide  analog  formed  by  covalently  linking  
3-(hexdecyloxy)propan-1-ol  to  cidofovir  (CDV),  is  being  developed  as  a  treatment  for 
smallpox. In the absence of human cases of smallpox, new treatments must be tested for 
efficacy  in  animal  models.  Previously,  we  demonstrated  the  efficacy  of  CMX001  in 
protecting New Zealand White rabbits from mortality following intradermal infection with 
rabbitpox virus as a model for smallpox, monkeypox and for treatment of adverse reactions 
to  smallpox  vaccination.  Here  we  extend  these  studies  by  exploring  different  dosing 
regimens  and  performing  randomized,  blinded,  placebo-controlled  studies.  In  addition, 
because  rabbitpox  virus  can  be  transmitted  via  naturally  generated  aerosols  (animal  to 
animal transmission), we report on studies to test the efficacy of CMX001 in protecting 
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rabbits  from  lethal  rabbitpox  virus  disease  when  infection  occurs  by  animal  to  animal 
transmission.  In  all  cases,  CMX001  treatment  was  initiated  at  the  onset  of  observable 
lesions in the ears to model the use of CMX001 as a treatment for symptomatic smallpox. 
The results demonstrate that CMX001 is an effective treatment for symptomatic rabbitpox 
virus infection. The rabbitpox model has key similarities to human smallpox including an 
incubation period, generalized systemic disease, the occurrence of lesions which may be 
used as a trigger for initiating therapy, and natural animal to animal spread, making it an 
appropriate model. 
Keywords: poxvirus; antiviral; CMX001; rabbitpox; smallpox treatment 
 
1. Introduction 
CMX001 is a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy)propan-1-ol 
to cidofovir (CDV). Cidofovir (marketed as Vistide
®), an antiviral drug approved for the treatment of 
CMV-retinitis  [1,2],  is  an  alternative  substrate  inhibitor  of  the  DNA  polymerases  encoded  by 
orthopoxviruses,  and  has  shown  activity  in  lethal  models  of  poxvirus  infection  using  mice  and 
monkeys [3–7]. Although CDV is the only antiviral drug currently available for use in the event of a 
smallpox outbreak, its utility in an attack would be limited since it must be administered by slow 
intravenous infusion and has the potential for significant nephrotoxicity [8,9]; currently there is no 
approved antiviral for treatment of smallpox. In an effort to address the need for an orally available 
antiviral drug for human poxvirus infections, a lipid conjugate of CDV was synthesized by covalently 
coupling CDV to hexadecylpropanediol; the resulting compound is referred to as CMX001 hereforth. 
The conjugate was designed to resemble a natural phospholipid and utilize natural uptake pathways to 
achieve oral availability, high uptake in target cells, and overall improved Absorption, Distribution, 
Metabolism, Excretion (ADME) profiles [10]. Because variola virus has been eliminated from the 
environment, no new cases of smallpox have been reported since 1977 [11] and therefore it is not 
possible to test the efficacy of potential treatments in human trials with smallpox. Rabbitpox virus 
infection of rabbits has been used as a model for smallpox as well as general orthopoxvirus infections 
of humans, such as monkeypox virus infections, since its discovery in the 1930s [12–16].  
We have used intradermal inoculation and natural aerosol (animal to animal) transmission to infect 
New  Zealand  White  (NZW)  rabbits  with  rabbitpox  virus  as  models  to  evaluate  the  efficacy  of 
CMX001 as a potential treatment for orthopoxvirus infection. Here we examine the effectiveness of 
CMX001 administered after virus exposure and in rabbits infected from index animals. Our results 
demonstrate that CMX001 is effective in preventing mortality and reducing morbidity when dosed 
after the onset of acute symptoms as measured by the presence of secondary lesions. Viruses 2011, 3                         
 
 
49 
2. Results and Discussion 
2.1. Regimen of CMX001 Required for Protection from Rabbitpox virus (RPV) Disease and Death 
In vitro studies with human PBMCs showed that the half life of the active metabolite of CMX001 
was up to 6.5 days [17] and in vitro data indicates that the active antiviral in common with CMX001 
and  cidofovir  (cidofovir  diphosphate)  has  a  long  intracellular  half  life  [18].  Therefore,  it  was 
hypothesized that a single treatment with CMX001 might be sufficient to prevent lethal RPV disease 
as described in the accompanying paper [19]. We tested the efficacy of CMX001 in intradermally 
infected rabbits when dosed one, two, or three times over the course of five days starting on 3 or 4 dpi 
(ear lesions typically occur beginning on 4 dpi). As shown in Table 1, all groups in which treatment 
was begun at 3 dpi survived RPV infection. The survival rate of animals beginning treatment at 4 dpi 
was 66% regardless of whether one, two or three doses of CMX001 were administered. The animal 
euthanized from the 4 dpi treatment group was due to severe respiratory disease, the animal euthanized 
from the 4/6 (4, 6 dpi) treatment group was due to weight loss and the animal from 4/6/8 (4, 6, 8 dpi) 
treatment group was removed due to severe respiratory distress. Thus it appeared that one to three 
doses of CMX001 were sufficient to provide a survival benefit. In fact, all groups receiving CMX001 
demonstrated  a  significant  survival  benefit  when  compared  to  the  pooled  vehicle  controls  across 
different experiments (14/14 mortalities) (data not shown). 
Table 1. Evaluation of 1, 2 or 3 doses of CMX001 given every other day beginning at  
day 3 or 4 post infection. CMX001 was administered once a day (QD). 
CMX001 Dose 
(mg/kg)  
Day of Dosing (dpi)  
Mean Time to  
Death ± SEM  
Survival at  
Day 14PI  
20  3  NA   3/3 (100%)*  
20   4   10 ± 0   2/3 (66%)  
20   3, 5   NA   3/3 (100%)*  
20   4, 6   7 ± 0  2/3 (66%)  
20   3, 5, 7   NA   3/3 (100%)*  
20   4, 6, 8   9 ± 0  2/3 (66%)  
Vehicle   Vehicle   9 ± 0  0/2 (0%)  
* p = 0.099 as compared to vehicle by unpaired t-test. 
 
The  animals  treated  with  CMX001,  regardless  of  the  number  of  doses  or  day  treatment  was 
initiated, exhibited less weight loss than the vehicle treated animals (Figure 1A and D). Both 3/5/7  
(3, 5, 7 dpi treated) and 4/6/8 treatment groups exhibited less weight loss and a return to weight gain 
more quickly than the single or double dosed treatment groups. There was little difference in weight 
change profiles between 3 and 3/5 (3, 5 dpi treated) and 4 or 4/6 (4, 6 dpi) treatment groups. 
All groups exhibited temperature spikes during the course of the experiment. Animals that received 
CMX001 once or twice exhibited a fever from 5 to 11 dpi while animals that received CMX001 three 
times exhibited a fever from 5 to 9 dpi with a lower overall maximum temperature (Figure 1B and E). 
Generally, the more times the rabbits were given CMX001, the less severe their temperature spikes 
were. The overall disease as measured by clinical scores over the course of the experiment showed a Viruses 2011, 3                         
 
 
50 
decrease in disease severity of all treatment groups as compared to vehicle treated animals (Figure 1C 
and  F).  There  was,  however,  little  difference  in  clinical  score  profiles  over  the  course  of  the 
experiment  between  any  of  the  treatment  groups  when  compared  to  number  of  doses  of 
CMX001 received.  
Figure 1. Clinical observations for evaluation of 1, 2 or 3 doses of CMX001 given every 
other day beginning at day 3 or 4 post infection. Animals were dosed at concentrations and 
schedules  as  outlined  in  Table  1.  (A)  Average  weight  change  from  weight  at  day  of 
infection  for  animals  that  began  treatment  on  day  3  post  infection.  Negative  values 
indicated weight loss. (B) Average body temperatures for animals that began treatment on 
day 3 post infection. (C) Average clinical scores for animals that began treatment on day 3 
post infection. (D) Average weight change from weight at day of infection for animals that 
began  treatment  on  day  4  post  infection.  Negative  values  indicated  weight  loss.  
(E) Average body temperatures for animals that began treatment on day 4 post infection. 
(F)  Average  clinical  scores  for  animals  that  began  treatment  on  day  4  post  infection.  
(G) Pictures of primary lesions (necrosis only) from representative animals at 7 dpi. Bars 
represent 1cm. Black circles denote site of intradermal inoculation. 
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The primary lesion in 3 and 4 dpi treatment groups was fairly large, covering a large area of the 
animals’  flank  and  showed  a  good  deal  of  necrosis.  Animals  in  these  treatment  groups  also  had 
numerous widespread secondary lesions localized mainly in the eyes, ears, and mouth. The animals 
from treatment groups 3/5 and 4/6 dpi exhibited smaller primary lesion sites and less severe necrosis 
with a moderate number of secondary lesions. Treatment groups 3/5/7 and 4/6/8 dpi exhibited fairly 
mild primary lesions characterized by less necrosis and less edema and swelling (Figure 1G) and had 
fewer secondary lesions, all localized mainly in the eyes, ears, and mouth. The primary lesions are 
characterized not only by the highly visible area of necrosis but also by the area of edema which 
defines the overall lesion size. The area of edema does not produce a swelling of the flank but rather a 
thickening of the skin up to 3 cm in depth and the photographs do not show this clearly.  
Using  the  maximum  clinical  score  and  weight  loss  as  indications  of  maximal  illness,  it  was 
observed that treatment with CMX001 provides a reduction in the disease severity for all treatment 
groups  (Figure  2A).  Animals  that  began  treatment  on  3  dpi,  regardless  of  number  of  doses  they 
received, exhibited a lower maximal clinical score over the course of the experiment suggesting the 
number of doses may not have an immense impact on outcome when initiated early in the disease. 
Similarly, among the animals treated starting at day 4, there was little difference in disease severity 
regardless of the number of doses the animals received. The maximum weight loss over the course of 
the experiment paralleled the maximal clinical score (Figure 2B). All animals that received treatment 
exhibited  a  less  severe  weight  loss  maximum  as  compared  to  the  vehicle treated  animals  and,  in 
general,  animals  that  began  treatment  at  4  dpi,  regardless  of  the  number  of  doses,  exhibited  less 
weight loss. 
Figure 2. Disease severity measurements for evaluation of 1, 2 or 3 doses of CMX001 
given  every  other  day  beginning  at  day  3  or  4  post  infection.  Animals  were  dosed  at 
concentrations and schedules as outlined in Table 1. (A) Average of maximum clinical 
scores  for  each  animal  per  group  over  the  course  of  the  experiment.  (B)  Average  of 
maximum percent weight loss from weight at day 0 for each animal per group over the 
course of the experiment. 
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2.2. Randomized, Blinded, Placebo Controlled Studies 
To  unequivocally  demonstrate  the  efficacy  of  CMX001,  we  performed  randomized,  blinded, 
placebo-controlled studies that were appropriately powered to achieve statistical significance. In this 
series  of  experiments,  rabbits  were  intradermally  inoculated  with  RPV  and  at  the  first  sign  of 
secondary lesions in the ears, CMX001 treatment was initiated for each rabbit on an individual basis. 
Both males and females were used to investigate the possibility of gender bias in this experiment as 
previous studies utilized only female rabbits. Rabbits were randomly assigned to treatment groups and 
blinded dosing formulations containing either CMX001 or vehicle were prepared by Chimerix and 
shipped to the University of Florida for testing. Due to limitations of study size, three separate studies 
(of  12  CMX001  treated  and  12  control  animals)  were  conducted.  Within  each  study,  all  rabbits 
received either one, two or three doses of blinded treatment, thus the number of doses was not blinded. 
There was a statistically significant increase in survival rates when CMX001 was administered to 
RPV infected rabbits as compared to vehicle treated age and sex matched control animals (Table 2) 
using Fisher’s exact test. A single dose of CMX001 protected seven of 12 animals while two doses 
protected eight of 12. For animals that received three doses of CMX001, 11 of 12 survived. In contrast, 
only four of 36 animals receiving vehicle only survived. There was no large difference in the day of 
death for any of the animals that were euthanized due to severe RPV induced disease. 
Table 2. Evaluation of efficacy of CMX001 when treatment is begun at the appearance of 
secondary lesions in the ears. Groups of 12 animals were treated with CMX001 1, 2 or 3 
times every other day beginning at the appearance of secondary lesions in the ears. 
CMX001 Dose 
(mg/kg)  
Frequency of 
Dosing  
Day Dosing 
Began (dpi)  
Mean Time to 
Death ± SEM  
Survival at 
Day 14PI  
20  1 dose   3 to 4  10.6 ± 0.24   7/12 (58.33%)  
20   2 doses   3 to 5   10.5 ± 0.96   8/12 (67.67%)  
20   3 doses  3 to 4   11 ± 0   11/12 (91.67%)  
Vehicle   NA  3 to 4   9.06 ± 0.18  4/36 (11.1%)  
 
All treatment groups exhibited weight loss over the course of the experiment; however the groups 
receiving  two  and  three  doses  of  CMX001  exhibited  less  weight  loss  as  compared  to  the  group 
receiving one dose of CMX001 and the vehicle treated group (Figure 3A). The temperature profiles for 
the groups were indistinguishable from that of the vehicle treated animals with all animals exhibiting 
fevers from 3 to 8 dpi (Figure 3B). There was a general trend for animals receiving a single dose of 
CMX001 to exhibit a higher temperature; this difference however was not statistically significant. 
There was a difference in clinical score profiles for the course of the experiment with the 3 dose group 
exhibiting a lower clinical score consistently (Figure 3C). Primary lesions in treated animals began to 
heal and decrease in size after the initiation of CMX001 treatment. The primary lesions are shown in 
Figure 6D at 8 dpi showing little difference between one and two doses of CMX001 as compared to 
three doses in which the primary lesions rapidly decreased in swelling and began scabbing. Viruses 2011, 3                         
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Figure  3.  Animals  treated  beginning  at  the  appearance  of  secondary  lesions.  Groups  
of 12 animals were treated with CMX001 1, 2 or 3 times every other day beginning at the 
appearance of secondary lesions in the ears. Animals were dosed at concentrations and 
schedules as outlined in Table 2. (A) Average weight change over time for each group. 
Negative  values  represent  weight  loss.  (B)  Average  body  temperatures  over  time. 
Temperatures over 39.5 °C  are considered a fever. (C) Average clinical score over time. 
Error bars represent SEM. (D) Photographs of primary lesions from each treatment group 
at 8 dpi. Bar represents 1cm. 
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Maximal illness over the course of the experiment was analyzed by the average maximum clinical 
score,  weight  change  and  primary  lesi on  size.  All  animals  treated  with  CMX001  exhibited  a 
statistically significant decrease in the maximum clinical score as compared to vehicle treated animals 
(Figure 4A). Within the treatment groups there was a general trend observed in which the more doses  
of  CMX001  received ,  the  less  severe  disease.   The  maximum  average  weight  change  again 
demonstrated a similar trend to that of clinical score in which the more doses of CMX001 animals 
received, the lower the weight loss observed (Figure 4B). There was a statistical decrease in the weight 
loss of two and three doses as compared to that of vehicle treated animals.  There was a decrease in 
average maximum size of the primary lesion as compared to vehicle treated animals for all CMX001 
treated groups (Figure 4C). No differences in the maximum lesion size among the CMX001 treatment 
groups were observed. The level of virus dissemination was evaluated in this experiment; however the 
results  were  uninformative  most  likely  due  to  limitations  of  live  virus  detection  met hods  (data 
not shown). Viruses 2011, 3                         
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Figure  4.  Disease  severity  measurements  when  CMX001  treatment  began  at  the 
appearance of secondary lesions. Animals were dosed at concentrations and schedules as 
outlined in Table 2. (A) Average of maximum clinical scores for each animal per group 
over the course of the experiment. (B) Average of maximum percent weight loss from 
weight at day 0 for each animal per group over the course of the experiment. (C) Average 
of maximum diameters of primary lesions of each animal per group over the course of 
the experiment. 
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2.3. Rabbitpox Infection via Natural Aerosol Model Review 
In addition to the ID route, lethal infection in the rabbit/RPV model can also occur by animal to 
animal  aerosol  transmission.  In  this  natural  aerosol  model  virus  transmission  occurs  from  index 
(1000 pfu  RPV  intradermally  infected)  to  sentinel  (uninfected)  animals.  Transmission  has  been 
observed when sentinel animals are either co-housed or in adjacent cages to the index animals [12] and 
is  believed to be very similar to the transmission that occurs in smallpox in humans. While it is 
difficult to determine the infectious dose in this natural animal to animal aerosol transmission model it 
is believed to be very low. This model utilizes the natural conditions under which RPV has been 
shown to transmit virus throughout rabbit colonies such as in Utrecht and Rockefeller University. The 
disease timeline is shown in Figure 5 for the sentinel co-housed animals. Viruses 2011, 3                         
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Figure 5. Time line of disease in 8–10 week old New Zealand White rabbits infected via 
natural aerosol. Symptoms in red boxes represent clinical measurements that contribute to 
euthanasia guidelines. Clinical symptoms are indicated in blue boxes. Reproduced with 
permission from American Society for Microbiology [12]. 
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While the amount of virus transmitted to the sentinel animals is not readily measured or controlled, 
the timing of sentinel animal infection can be inferred by a reverse tracing of clinical symptoms.  
Although it is possible that some rabbits may become  inoculated via routes other than the respiratory 
tract, we have examined this issue and have never found any evidence of primary skin lesions on 
infected sentinel animals nor were  we able to induce infections of sentinel through waste material 
derived from infected sentinel animals [20]. Indeed, the only difference clinically between infected 
index (intradermally infected) and sentinel (animal to animal natural aerosol infected) animals is a 
neck swelling of sentinel animals (Figure  7D) which is similar to  what we observe in intranasally 
infected rabbits [21] and consistent with an aerosol inoculation from index animals [13]. 
There is a 23.1% survival rate of natural aerosol infected animals (Figure  6A). The difference in 
survival rates as compared to the hi ghly lethal intradermal infected rabbits is perhaps due to dose; 
10 to 100 times more RPV is required to cause lethal disease when virus is administered intranasally  
[21].  The first clinical signs of systemic disease following animal   to  animal transmission  are the 
presentation of a fever (Figure 6C) and failure to gain weight (Figure 6B) that begin 9-10 dpi. Weight 
loss is approximately 10% from the maximum weight during the course of the experiment and occurs 
at 13 dpi. The severity of fever observed following animal to animal transmission is 40.6 °C ± 0.72 
on 14 dpi and not statistically or biologically different from that observed with intradermally infected 
animals with a maximum temperature of 40.8 °C ± 0.34 on 5 dpi. The severity of disease is quantified 
using the clinical score (Figure  6D); RPV infected animals exhibit severe disease with an average 
maximum clinical score of 13.89 ± 1.43 points out of a possible 25 points (note that the natural aerosol 
infected animals have a lower maximum score because no primary lesion is present).  
Secondary lesions are observed in the ears first and generally appear 12–24 hours after the first sign 
of a fever is observed, following the same disease progression as intradermally infected animals. The 
lesions first appear in the ears as small red spots typically found at the bend of a blood vessel and are 
easily visualized by backlighting the ears. The progression of these small red spots to pustular lesions 
on the ears is shown in Figure 7A. We have noted that the ear lesions are larger and more pronounced 
in aerosol infected animals. Secondary lesions are also found on the nose, eyelids (Figure 7B), in and 
around the mouth, genitals and as a rash across the body of the rabbit. Viruses 2011, 3                         
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Figure 6. Disease in rabbits lethally infected with RPV via natural aerosol. (A) Survival of 
naturally  infected  rabbits  (sentinel),  infected  cage  mates  providing  aerosolized  RPV 
(index) and uninfected control animals (PBS). (B) Average weight change from weight at 
time of infection for each group. Negative values represent weight loss. (C) Average body 
temperatures over time. Temperatures over 39.5 °C are considered a fever. (D) Average 
clinical  score  over  time.  Error  bars  represent  SEM.  Reproduced  with  permission  from 
American Society for Microbiology [12]. 
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Animals infected with RPV are euthanized due to respiratory distress characterized by open mouth 
breathing, a decrease in respiration rate to below 40 breaths per minute or severe lung sounds.  The 
respiratory  symptoms  begin  at  approximately  1 0  dpi  and  progress  to  euthanasia  criteria  levels   
by 12–17 dpi. At the time of euthanasia it is typical to observe profuse mucopurulent discharge from 
the nostrils (Figure 7C) and severe discharge from the eyes. 
RPV in rabbits share many features of variola in humans. In addition to the fact that replication and 
spread of RPV and variola within the host are believed to be very similar [11] and both viruses spread 
by natural aerosol transmission [22–25]. While there are some differences between RPV via natural 
aerosol  transmission  to  variola,  including  a  shortened  incubation  period,  both  viruses  produce  a 
systemic  viremia  and  characteristic  dermal  rash.  The  natural  aerosol  transmission  of  RPV  is  an 
important  model  for  evaluating  both  antivirals  and  vaccines  as  it  is  the  closest  model  to  human 
exposure to smallpox currently available.  
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Figure 7. Presentation of disease in rabbits infected by aerosol transmitted RPV. Rabbits 
were infected as described in Figure 5. (A) Secondary lesions observed in the ears of 
animals exposed to RPV via aerosol. Arrows show locations of 2 representative lesions in 
the ear. (B) Photograph of a secondary lesion on the eye of an animal marked with arrow. 
(C)  Normal  profile  of  intradermally  lethally  infected  RPV  rabbit  nose.  (D)  Profile  of 
aerosol infected RPV rabbit showing severe swelling of nose and muzzle. Reproduced with 
permission from American Society for Microbiology [12]. 
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2.4. Treatment of Natural Aerosol Infected Animals 
The efficacy of CMX001 in rabbits infected with RPV by natural aerosol was investigated. Sentinel 
animals were co-housed with index animals intradermally inoculated with 1000 PFU of RPV. Sentinel 
animals develop ear lesions and an elevated temperature at 8–10 days after infection of the index 
animal,  suggesting  sentinels  received  virus  from  the  intradermally  infected  index  animals  at  
about 4–6 days after the initial intradermal infection. The sentinel rabbits were then observed for the 
development of secondary lesions as a trigger to initiate CMX001 treatment. Animals were given a 
total of one, two or three doses of CMX001 (20 mg/kg per dose) spaced every other day beginning on 
the day secondary lesions were detected in the ears of the animals. Secondary lesions appeared in the 
sentinel animals between seven and nine days post infection of the index animals. No vehicle-treated 
animals  survived,  however  two/three  of  the  animals  in  each  CMX001  treatment  group 
survived (Table 3). 
Table 3. Evaluation of efficacy in natural aerosol infected animals. Groups of 3 animals 
were treated with CMX001 1, 2 or 3 times every other day beginning at the appearance of 
secondary lesions in the ears. 
CMX001 Dose 
(mg/kg)  
Frequency of 
Dosing  
Day Dosing 
Began (dpi)  
Mean Time to 
Death ± SEM  
Survival at 
Day 14PI  
20  1 dose   7 to 8  18 ± 0   2/3 (66%)  
20   2 doses   7 to 9   13 ± 0  2/3 (66%) 
20   3doses  7 to 9   16 ± 0  2/3 (66%) 
Vehicle   NA   NA   14.3 ± 1.3  0/3 (0%)  
 
Overall, the CMX001 treatment groups exhibited less severe disease as compared to vehicle treated 
animals. CMX001 treated animals exhibited a trend of less weight loss than vehicle treated animals Viruses 2011, 3                         
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(Figure 8A). All animals exhibited a fever (body temperature of 39.5 °C or higher), however animals 
receiving  CMX001  tended  to  have  lower  average  maximum  temperatures  as  compared  to  vehicle 
treated animals (Figure 8B). All animals developed RPV disease symptoms as shown by the profiles of 
clinical scores for each group (Figure 8C). Again, as observed with weight loss and degree of fevers 
observed, animals receiving CMX001 tended to show less severe disease and did not develop the 
disease on average as quickly as the vehicle treated animals. While the number of animals in this study 
was small, making statistical significance difficult to achieve, the data obtained suggest that CMX001 
is effective in treating rabbits infected with RPV via the aerosol route and therefore supports the use of 
CMX001 against smallpox in humans where exposure is via aerosol. 
Figure 8. Aerosol infected animals treated beginning at the appearance of secondary lesions. 
Groups of 3 animals were treated with CMX001 1, 2 or 3 times every other day beginning at 
the appearance of secondary lesions in the ears. Animals were dosed at concentrations and 
schedules as outlined in Table 3. (A) Average weight change over time for each group. 
Negative  values  represent  weight  loss.  (B)  Average  body  temperatures  over  time. 
Temperatures over 39.5 °C are considered a fever. (C) Average clinical score over time. 
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3. Experimental Section 
3.1. Cell and Virus Growth 
CV-1 cells were maintained in Minimum Essential Media (MEM) with Earle’s Salts (Gibco, New 
York, USA) supplemented with 2 mM glutamine (Media Tech, Virginia, USA), 50 U/mL penicillin G 
and  50  µg/mL  streptomycin  (Media  Tech),  1  mM  sodium  pyruvate  (Media  Tech),  and  0.1  mM 
nonessential amino acids (Media Tech), and 10% v/v FBS (Gibco). 
Rabbitpox  virus  (RPV)  was  obtained  from  ATCC  and  virus  stocks  used  in  these  experiments 
were ≤5 passages from the original stock and have maintained virulence as evidenced by an LD50 
in 9-week old NZW rabbits of approximately 10 PFU by the intradermal route. All viruses for animal 
infections  were  pad  purified  over  36%  sucrose  using  standard  methods  and  resuspended  in  PBS. 
Viruses were tittered on CV-1 cells using standard methods. [26,27] 
3.2. Housing of Animals 
For intradermally infected rabbits, 8 week (3–4 lb) old New Zealand White rabbits were obtained 
from Myrtle’s Rabbitry (Thompson Station, Tennessee, USA) and housed in standard stainless steel Viruses 2011, 3                         
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solid back and side cages at 20 °C and 12 h light / 12 h dark regime. All animals obtained a unique ear 
tattoo number in the left ear prior to arrival at the study site. Animals were allowed to acclimate to 
their surroundings for 5–10 days prior to RPV infection. Food and water were available to the animals 
ad libitum. Rabbits received apples, alfalfa cubes, or fresh greens daily for enrichment. 
For  animal  to  animal  natural  aerosol  transmission  studies,  six  rabbits  were  co-housed  in  a 
160 × 80 cm  cage  with  shredded  paper  bedding  and  fed  ad  libitum.  Two  rabbits  were  infected 
intradermally  with  RPV as  described  previously  (index  animals)  and housed with  four uninfected 
rabbits (sentinel animals). Upon onset of severe respiratory disease, the index animal was euthanized. 
At the appearance of secondary lesions the sentinel animals were transferred to a standard steel single 
rabbit housing cage for the remainder of the experiment. 
All animal procedures were approved by the University of Florida Institutional Animal Care and 
Use Committee. 
3.3. Animal Infections 
Intradermal infection was performed by bilateral shaving of both thighs of the rabbit, sterilizing 
with an isopropanol wipe followed by intradermal injection of 100 or 1000 pfu RPV using a 27 gauge 
needle  [12].  The  injection  site  was  then  traced  using  a  black  permanent  marker  to  note  the  site 
of infection. 
3.4. Monitoring of Animals 
Rabbit  were  microchipped  at  the  time  of  infection  to  transmit  body  temperature  and  unique 
identification number (Bio Medic Data Systems, Seaford, DE). Rabbits underwent a complete physical 
daily. Rabbits were euthanized upon the onset of severe respiratory distress (labored, extremely slow 
or open mouth breathing) or weight loss of greater than 15% of initial body weight. 
Clinical scores for each rabbit each day were generated by assigning numerical values of 0 to 4 for 
all  clinical  measurements  obtained  during  the  course  of  the  evaluation  of  each  rabbit.  These 
measurements  included:  Weight  change  (loss,  no  change  or  gain);  body  temperature  (low,  within 
normal limits, fever); respiration rate (normal, depressed); heart rate (normal, decreased); intake and 
output; overall attitude and posture; presence of secondary lesions (number of secondary lesions and 
number of sites present); and primary site of infection condition (degree of reaction). These scores are 
used as a measure of disease severity where the higher the number the more severe the disease. 
Weight change was calculated as the percent change from weight on the day of infection with RPV. 
All statistical analysis is performed using an unpaired t test for each group measurement as compared 
to vehicle treatment groups. 
All  animal  procedures  and  euthanasia  were  carried  out  according  to  the  University  of  Florida 
IACUC guidelines. 
3.5. CMX001 Dosing of Animals 
Animals were trained for 4–5 days prior to the initiation of the study to readily accept the 10% 
sucrose solution used to deliver CMX001 (HDP-CDV). The 10% sucrose training solution, vehicle Viruses 2011, 3                         
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solution and CMX001 was administered orally using a 1 ml disposable syringe with the end dipped in 
granulated sugar and fed orally to the animals. The total volume of liquid the animals received was 
approximately 1.0 mL. Dry powdered CMX001 (Chimerix Inc, North Carolina, USA) was dissolved in 
10%  sucrose  in  water  with  food  coloring  to  the  required  concentration.  Vehicle  treated  animals 
received  10%  sucrose solution only. In a previous pharmacokinetic study, all rabbits treated with 
CMX001 for seven days at doses up to 25mg/kg/day survived to the scheduled termination. In this 
special issue there is a review on the development of CMX001 for further toxicological data. 
4. Conclusions 
Previously, we demonstrated the efficacy of CMX001 in protecting New Zealand White rabbits 
from mortality following intradermal infection with rabbitpox virus as a model for smallpox. Here we 
extended these studies by exploring different dosing regimens and performing randomized, blinded, 
placebo-controlled studies. Lesions in the ears are the result of systemic viral spread within the animal 
and the first appearance of ear lesions was used in these studies as a trigger to initiate treatment to 
model  how  smallpox  might  be  recognized  and  treated  in  the  event  of  a  release.  CMX001  was 
administered orally as a single dose of 20 mg/kg, two doses of 20 mg/kg (one dose on the day of 
lesions and a second dose two days later) or three doses of 20 mg/kg (one dose on the day of lesions 
with additional doses two and four days later). In randomized, blinded, placebo-controlled studies, 
treatment  of  intradermally  infected  rabbits  with  CMX001  at  the  first  appearance  of  ear  lesions 
provided a significant survival benefit compared to vehicle treated animals. This was true for each 
CMX001 treatment group regardless of the number of doses. The need for relatively few doses of 
CMX001  is  most  likely  explained  by  the  long  half-life  of  the  active  antiviral  species,  cidofovir 
diphosphate, in cells. After entering the cell, the lipid moiety of CMX001 is removed by cellular 
phospholipases to release free cidofovir which is then anabolized to the active antiviral form, cidofovir 
diphosphate. Cidofovir diphosphate is a nucleoside triphosphate mimic and is incorporated by the viral 
DNA polymerase. Despite the efficacy of the single dose treatment, the three dose treatment appeared 
to result in an improved survival rate and reduced disease severity. 
We also explored the efficacy of CMX001 treatment in animals infected via a natural aerosol, 
which provides an animal to animal transmission model of orthopoxvirus infections. In this model, 
index animals were intradermally inoculated and then co-housed with sentinel animals to allow for 
transmission of the infection to the uninfected animals. The sentinel animals were then treated with 
CMX001 at the first signs of lesions in the ears. As with the intradermal infection model, one, two, or 
three  doses  of  CMX001  appeared  to  significantly  reduce  disease  symptoms  and  have  a 
survival benefit. 
Overall, the results presented demonstrate that CMX001 is an effective treatment for symptomatic 
rabbitpox virus infection in rabbits. Attributes of the rabbitpox model including an incubation period, 
generalized systemic disease, the occurrence of lesions which may be used as a trigger for initiating 
therapy, and natural animal to animal spread make it a particularly relevant model for smallpox in 
humans.  The  delay  of  treatment  initiation  and  dosage  flexibility  demonstrate  the  feasibility  of 
CMX001 for use in treatment of any orthopox virus infections in humans. Viruses 2011, 3                         
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